Clopidogrel Bisulfate is a P2Y12 platelet inhibitor indicated for reduction of thrombotic events after acute coronary syndrome, recent myocardial infarction, stroke or peripheral arterial disease. We supply it to US manufacturers of tablets.
Data from PubChem (CID 115366) and FDA’s substance registry
CAS number
120202-66-6
Molecular formula
C16H18ClNO6S2
Molecular weight
419.9g/mol
FDA UNII
IUPAC name
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate;sulfuric acid
InChIKey
FDEODCTUSIWGLK-RSAXXLAASA-N
- Appearance
- White to off-white powder.
- Solubility
- Practically insoluble in water at neutral pH and freely soluble at pH 1.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Exists as polymorphic Forms I and II, and sources hold separate filings for each. State the form, and check the limit for the inactive R-enantiomer.
On the US market
- Reference product
- PlavixNDA 020839
- Approved ANDAs
- 16 with a marketed product
- Approved forms and strengths
- Tablet 75 mg, 300 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com